造血干细胞移植治疗恶性淋巴瘤的临床疗效

Clinical efficacy of hematopoietic stem cell transplantation in treatment of malignant lymphoma

摘要:

评价大剂量放化疗联合自体造血干细胞移植治疗高危恶性淋巴瘤序贯白介素2生物治疗的效果。方法分析20例高危、复发难治恶性淋巴瘤患者行自体造血干细胞移植前后免疫功能的变化。治疗组加用白介素2治疗后检测其免疫功能前后变化，并对治疗、对照组患者进行生存时间分析。结果治疗组移植后6 个月CD4+水平值为（24.29±3.64），高于对照组（20.23±2.14）；CD4/CD8 为（0.56±0.35）高于对照组（0.30±0.11），自然杀伤细胞水平（17.46±10.20）高于对照组（14.41±8.10），组间比较，差异有统计学意义（p <0.05）。结论移植后加用白介素2 免疫治疗，能有效改善移植患者免疫功能，延长患者生存时间。

Abstract:

To evaluate the effect of sequential IL-2 biological treatment on high-risk malignant lymphoma after high-dose radiochemotherapy combined with autologous hematopoietic stem cell transplantation. Methods The changes of immune function before and after autologous hematopoietic stem cell transplantation were analyzed in 20 cases of high-risk, relapsed and refractory malignant lymphoma patients. The immune function was detected before and after additional IL-2 treatment in the treatment group, and the survival time was analyzed in both treatment and control groups. Results Six months after transplantation, the CD4+ cell level in the treatment group (24.29 ±3.64) was higher than that in the control group (20.23 ±2.14), CD4+/CD8+ of the treatment group (0.56 ±0.35) was higher than that of the control group (0.30 ±0.11), the NK cell level of the treatment group (17.46 ±10.20) was higher than that of the control group (14.41 ±8.10), the differences were statistically significant (p < 0.05). Conclusions After autologous hematopoietic stem cell transplantation, IL-2 immune therapy can significantly improve the immune function of the patients with high-risk malignant lymphoma, and prolong their survival time.